We are international

Sydney 2005:
New Therapeutic Approaches in Myeloma Bone Disease
By Claire Shipman, MD
Dr. Shipman opened discussed the interactions between tumor cells and cells in the bone marrow (osteoclasts and osteoblasts) that may influence systems that are involved in the development of bone disease in patients with MM. Myeloma cells may be under the influence of certain molecules (OPG) that support their survival in the bone marrow. Preliminary data from a few patients shows that MGUS cells produce OPG but MM cells may rarely or may not produce OPG. Similarly, cells in the bone marrow microenvironment may protect myeloma cells from factors that would induce apoptosis and thus limit the progression of disease. One of these factors, TRAIL, may mediate antitumor activity.

Back to session summary

 related articles